PATENT AND TRADEMARK OFFICE FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)	SERIAL NO.: 10/754,364
APPLICANT: MITHCEL F. BRIN	TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
(ab	AA	09/371,354		Donovan, Stephen			8/10/1999
leb.	AB	10/114,740		Brooks, Greg			4/1/2002
(0/0	AC	10/194,805		Donovan, Stephen		·	7/11/2002
(0)0	AD	5,437,291	8/1/1995	Pasricha et al.			
Leb	AE	5,670,484	9/23/1997	Binder, William			
Com	AF	5,714,468	2/3/1998	Binder, William			
(06	AG	5,766,605	6/16/1998	Sanders et al.			
un	ĀH	5,989,545	11/23/1999	Foster et al.			
(0)0	Al	6,063,768	5/16/2000	First, Eric			
(0)	AJ	6,139,845	10/31/2000	Donovan, Stephen			,
les	AK	6,265,379	7/24/2001	Donovan, Stephen			
W	AL	6,299,893	10/9/2001	Schwartz et al.			
lep	AM	6,306,423	10/23/2001	Donovan et al.			
Leb	AN	6,312,708	11/6/2001	Donovan, Stephen			
Levo	AO	6,358,926	3/19/2002	Donovan, Stephen			
less	AP	6,423,319	7/23/2002	Brooks et al.			
les	AQ	6,458,365	10/1/2002	Aoki et al.			
leb	AR	6,464,986	10/15/2002	Aoki et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
(lh	BA	WO 01/10458	2/15/01	PCT			Yes
1020	BB	WO 03/084567	10/16/03	PCT			Yes

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Bigalke H., et al., Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic
leh		Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360;318-
		324:1985

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PATENT AND TRADEMARK OFFICE FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)	OIPE	SERIAL NO.: 10/754,364
APPLICANT: MITHCEL F. BRIN	MAR 0 4 2004	TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004	A PRADEMARKO	GROUP:

1	СВ	Bigalke H., et al., Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake
les	1	of Various Transmitters, as Studied with Particulate Preparations From Rat Brain
		and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981
, .	CC	Binz T. et al., The Complete Sequence of Botulinum Neurotoxin Type A and
leb		Comparison with Other Clostridial Neurotoxins, J Biological Chemistry
00 /		265(16);9153-9158:1990
leh	CD	Bushara K., Botulinum toxin and rhinorrhea, Otolaryngol Head Neck Surg
(COV)	105	1996;114(3):507
Leb	CE	Duggan et al., A Survey of Botulinum neurotoxin substrate expression in cells; Mov
COV		Disord, 10(3):376:1995
	CF	Gonelle-Gispert et al., Snap-25a and -25b isoforms are both expressed in insulin-
(eb)		secreting cells and can function in insulin secretion; Biochem J 1;339 (pt 1):159-
	-	65:1999
1 .	CG	Habermann E., et al., Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit
leb		Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51(2);522-
	011	527:1988
/ .	СН	Habermann E., Inhibition by Tetanus and Botulinum A Toxin of the release of
leb		[3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate, Experientia
		44;224-226:1988
leb	CI	Harrison's Principles of Internal Medicine (1998), edited by Anthony Fauci et al.,
0.5	 	14th edition, published by McGraw Hill
les	CJ	Jankovic J. et al., <i>Therapy With Botulinum Toxin</i> , Marcel Dekker, Inc., (1994), page
000	CK	5, 150
Les	СК	Moro E., et al, Suppression of syncopes after botulinum toxin treatment, Mov Disord
	CI	2002;17(Suppl 5):S242 ABS P780
	CL	Moyer E et al., Botulinum Toxin Type B: Experimental and Clinical Experience,
les		being chapter 6, pages 71-85 of "Therapy With Botulinum Toxin", edited by
	CV	Jankovic, J. et al. (1994), Marcel Dekker, Inc.
,	СМ	Naumann et al., Botulinum toxin type A in the treatment of focal, axillary and palmar
l W		hyperhidrosis and other hyperhidrotic conditions; European J. Neurology 6 (Supp
	Chi	(4): S111-S1150:1999
les	CN	Pearce, L.B., Pharmacologic Characterization of Botulinum Toxin For Basic Science
	-	and Medicine, Toxicon 35(9);1373-1412 at 1393
les	СО	Ragona et al., Management of Parotid Sialocele with Botulinum Toxin; The
	L	Laryngoscope 109:1344-1346:1999

EXAMINER GARAGE MATE CONSIDERED 1/11/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PATENT AND TRADEMARK OFFICE FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)	OIPE	SERIAL NO.: 10/754,364
APPLICANT: MITHCEL F. BRIN	MAR 0 4 2004 E	TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004	TRADEMARK	GROUP:

les	СР	Sanchez-Prieto, J., et al., <i>Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes</i> , Eur J. Biochem 165;675-681:1897
les	ca	Sterodimas, A., et al., Successful use of botulinum toxin-A for the treatment ofneck and anterior chest wall flushing, Clinical and Experimental Dermatology, 2003 Blackwell Publishing Ltd., Vol. 28, Pg. 592-594
Ces	CR	Schantz, E.J., et al, <i>Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine</i> , Microbiol Rev. 56;80-99:1992
Ces	CS	Singh, <i>Critical Aspects of Bacterial Protein Toxins</i> , pages 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1976)
(eb	СТ	Sloop et al., Reconstituted Botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use; Neurology, 48:249-53:1997.
les	CU	Tugnoli V., et al., The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A, Clin Auton Res 2002;12(3):174-178

AUG 0 5 2004

Sheet _1 of **?**/

IST OF ARECITED BY APPLICANT

ATTY. DOCKET: 17641 (BOT)	SERIAL NO.: 10/754,364
APPLICANT: MITCHELL F. BRIN	TITLE: METHODS FOR TREATING VASCULAR DISORDERS
FILING DATE: January 8, 2004	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	•					
	AB						
	AC						
	AD						
	AE						
	AF						
	AG				,		••
	АН						
	Al						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

les	CA	Kellogg, Jr., Dean L., et al., <i>Cutaneous Active Vasodilation in Humans is Mediated by Cholinergic Nerve Cotransmission</i> , Vol. 77(6), Dec. 1995, American Heart Association, Inc., Lippincott Williams & Wilkins, pp. 1222-1228.
	СВ	
	CC	
ļ	CD	
	CE	

EXAMINER_	lora	beigh	/ 0		1/11/05
*EXAMINER: Ini	tial if referen	ce considered,	whether or no	t citation is in conformance with MPEP 609;	Draw line through citation if

not in conformance and not considered. Include copy of this form with next communication to applicant.